Research programme: protein-protein inhibitors - Eisai/Paoli Calmettes

Drug Profile

Research programme: protein-protein inhibitors - Eisai/Paoli Calmettes

Alternative Names: PPI - Eisai/Paoli Calmettes

Latest Information Update: 19 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eisai Inc
  • Developer Eisai Inc; Paoli-Calmettes-institute
  • Class Antineoplastics
  • Mechanism of Action Protein-protein interaction inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 03 Nov 2015 Eisai Inc. and Paoli Calmettes agree to co-develop protein-protein inhibitors for treatment of Cancer
  • 03 Nov 2015 Investigation in Cancer in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top